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ABSTRACT
Acinetobacter species are emerging as an important nosocomial pathogen. Multidrug-resistant Acinetobacter 
spp. has limited the option for effective treatment. Although carbapenems are effective for the treatment 
of such infections, resistance to this drug has recently been reported. This study was undertaken to assess 
resistance to carbapenem in clinical isolates of Acinetobacter spp. from hospitalized patients by both disc-
diffusion and minimum inhibitory concentration (MIC) methods. All clinical samples from suspected cases 
of nosocomial infections were processed, and 265 isolates were identified as Acinetobacter species. These 
isolates were tested for antibiotic resistance by the disc-diffusion method with 14 antimicrobials, including 
meropenem and imipenem. Thereafter, all Acinetobacter species were subjected to MIC for meropenem. More 
than 80% resistance to second- and third-generation cephalosporins, aminoglycosides, and quinolones was 
recorded. Thirty percent of the strains were resistant to cefoperazone/sulbactam. Resistance to meropenem 
was observed in 6.4% of Acinetobacter spp. while 8.3% of the isolates showed intermediate resistance detected 
by MIC. All carbapenem-resistant/intermediate strains were also resistant to other (>10) antibiotics tested 
by the disc-diffusion method. The rising trend of resistance to carbapenem poses an alarming threat to the 
treatment for such infections. Regular monitoring, judicious prescription, and early detection of resistance to 
carbapenem are necessary to check further dissemination of drug resistance in Acinetobacter spp.
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INTRODUCTION
Although genus Acinetobacter was originally iden-
tified in the early 20th century, it was recognized as 
a ubiquitous pathogen only in the last decade (1). 
Acinetobacter baumannii, a member of the Acine-
tobacter calcoaceticus—A. baumannii complex, 
makes up to 73% of all Acinetobacter spp. and is 
the most commonly-involved pathogen in clinical 
infections (2). During the last decade, hospital-ac-
quired infections involving multidrug-resistant A. 
baumannii isolates have been reported, often in 
association with contamination of hospital equip-
ment or cross-contamination by colonized hands 
of personnel attending patients (1). Initial concern 
about multidrug-resistant and carbapenem-resis-
tant Acinetobacter baumannii (CRAB)-associated 
infections began when the first hospitalwide out-
break occurred in New York city in 1991 (3). Since 
then, reports of CRAB have been accumulating 
from other parts of the world (4), including India 
(5). Currently, the spread in hospital populations 
of resistant microorganisms is of great concern 
worldwide, suggesting that we may be approach-
ing the post-antimicrobial era (6). This study was 
undertaken to assess resistance to carbapenem in 
clinical isolates of Acinetobacter spp. from hospital-
ized patients by both disc-diffusion and minimum 
inhibitory concentration (MIC) methods.
MATERIALS AND METHODS
Duration and place of study
A three-year study (2003-2006) was conducted to 
determine the susceptibility of nosocomial isolates 
of Acinetobacter spp. to different antimicrobials, in-Gaur A et al. Carbapenem-resistant Acinetobacter species
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cluding imipenem and meropenem. Various speci-
mens were collected from patients admitted to 
different wards and intensive care unit of S.S. 
Hospital, Banaras Hindu University, Varanasi, In-
dia.
Identification of Acinetobacter spp.
Isolation of Acinetobacter spp. was done. Briefly, all 
clinical specimens were initially processed to sepa-
rate the oxidase-negative, non-fermenters from 
other gram-negative bacilli. Thereafter, identifi-
cation was done to confirm Acinetobacter spp. by 
standard protocol (7). 
In vitro susceptibility
Susceptibility to various antimicrobial agents was 
determined by the disc-diffusion method and MIC 
by the agar dilution method following the guide-
lines of Clinical and Laboratory Standards Institute 
(CLSI). Antimicrobial susceptibility testing was 
performed on Mueller Hinton agar by the disc-
diffusion method for the following antimicrobial 
agents (Hi-Media, Mumbai, India) with their con-
centration given in parentheses: cefotaxime (30 
μg), ceftazidime (30 μg), cefoperazone (75 μg), 
ciprofloxacin (05 μg), norfloxacin (10 μg), ami-
kacin (30 μg), gentamicin (10 μg), tobramycin 
(10 μg), netilmicin (30 μg), piperacillin (100 μg), 
carbenicillin (100 μg), cefoperazone/sulbactam 
(75 μg/30 μg), meropenem (10 μg), and imipenem 
(10 μg) by the Kirby-Bauer method. Further in vitro 
susceptibility was determined for meropenem (As-
traZeneca, India) by MIC with the agar dilution 
method, and results were interpreted according to 
the guidelines of CLSI (≤4 μg/mL=sensitive, 8 μg/
mL=Intermediate, and ≥16 µg/mL=resistant). 
Quality control of susceptibility testing was done 
using ATCC 27853 Pseudomonas aeruginosa.
RESULTS
In total, 265 Acinetobacter spp. were isolated from 
1,242  culture-positive  samples  from  hospitalized 
patients and were identified up to species level as A. 
baumannii (91%) and A. Iwoffii (9%). On perform-
ing disc-diffusion for antimicrobial susceptibility, 
Acinetobacter spp. showed more than 80% resistance 
to third-generation cephalosporins. Among quino-
lones, 81% of the isolates were resistant to ciproflox-
acin, while norfloxacin was inactive in 78% cases 
of nosocomial urinary tract infection (UTI) caused 
by Acinetobacter spp. Among aminoglycosides, al-
though amikacin was relatively effective, still 74% 
of Acinetobacter spp. showed resistance to it. Cefo-
perazone/sulbactam  combination  was  effective 
with an overall resistance of 31% while 98% of Aci-
netobacter spp. were resistant to piperacillin. Among 
carbapenems, 9.1% of the isolates were resistant to 
imipenem and 9.8% to meropenem (Table 1).
On performing MIC, 39 isolates of Acinetobacter 
spp., which were resistant to meropenem, showed 
6.4% and 8.3% of absolute and intermediate resis-
tance respectively. These 39 isolates were recovered 
from 34 patients whose clinical data revealed that 
most of these isolates were from patients admitted 
to intensive care units (Table 2). On further analy-
sis, it was observed that 44.9% of the isolates were 
on borderline to the moderate/resistance range 
(Fig.). Interestingly, all carbapenem-resistant/inter-
mediate strains of Acinetobacter spp. were also resis-
tant to 12 other antibiotics tested by the disc-diffu-
sion method.
DISCUSSION
In the present study, an overall 18% isolation of 
Acinetobacter species in nosocomial colonization/
infections  was  observed.  Acinetobacter  species  ac-
counted for 1.4% of all nosocomial infections dur-
ing 1971-1981 in a university hospital in the Unit-
ed States (8). A more recent study in a university 
hospital found that hospitalization in an intensive 
care unit and previous administration of antibiotics 
were associated with Acinetobacter colonization at 
various sites of the body in 3.2-10.8 per 1,000 pa-
tients (9). Contrary to the previous studies, a higher 
prevalence of Acinetobacter spp. in the region could 
be due to lack of good infection-control practices, 
personal hygiene, over-crowding situations in infir-
mary, and heavy patient load. 
In this study, more than 75% of the isolates were 
resistant to third-generation cephalosporins, ami-
noglycosides, and quinolones. Other studies on 
Acinetobacters have depicted similar results with 
respect to these antibiotics (10-13). Thirty-one per-
cent of these isolates was resistant to cefoperazone-
sulbactam; the efficacy of this drug was significant 
(p<0.001) compared to other groups of antimicro-
bials. However, another study showed 46% resis-
tance to cefoperazone-sulbactam by the disc-diffu-
sion method (11). 
Resistance to meropenem was observed in 9.8% 
of Acinetobacter spp. by the disc-diffusion met-
hod while 6.4% and 8.3% of the isolates were re-
sistant and intermediate respectively by MIC. Till 
date, there are limited reports from India on resis-
tance to carbapenem, confirmed by MIC, in the Gaur A et al. Carbapenem-resistant Acinetobacter species
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nosocomial isolates of Acinetobacter species (5,14). 
Taneja et al. reported a high incidence (>20%) of 
resistance to carbapenem among Acinetobacters in 
India. However, a report from France showed that 
17% of Acinetobacter spp. was resistant to meropen-
em by the agar dilution method while a study 
in the UK reported 10% resistance which is quite 
similar to our results (15,16). 
Other studies have shown a high incidence of resis-
tance to carbapenem among Acinetobacters from 
patients in intensive care units, suggesting that in-
tensive care units are the epicentre for carbapenem-
resistant Acinetobacters (17,18). 
Meropenem-resistant Acinetobacter spp. was also 
found to be resistant to all other antimicrobials 
(Pandrug-resistant Acinetobacter baumannii) (19). 
This disturbing situation could be attributed to the 
increased use of antibiotics which has to be con-
trolled by a strict policy for use of antibiotics, in 
the face of aggressive marketing by the pharma-
ceuticals. Effective strategies, such as strict infec-
tion-control measures, judicious prescriptions of 
antibiotics, antimicrobial resistance surveillance 
programmes, and antibiotic cycling have all been 
tried successfully to control drug resistance in some 
countries (20).
Carbapenems have become the drugs of choice in 
Acinetobacter-associated infections in many centres 
but are slowly being compromised by the emer-
gence of carbapenem-hydrolyzing-lactamases of 
molecular class B and D (19). Class B carbapene-
mases found so far in Acinetobacters include various 
IMP and VIM types; class D enzymes include mem-
bers of the OXA-23- and OXA-24-related families 
and various unsequenced types (20). Loss of porins, 
PBP with reduced affinity, efflux pump, AmpC, and 
different class B and D ß-lactamases have been as-
sociated with resistance to carbapenems in clinical 
strains of Acinetobacter spp. (21,22). A report from 
India on mechanisms of carbapenem resistance 
(phenotypic method) among Acinetobacters has 
suggested that AmpC is responsible for such resis-
tance (5). 
Despite the low prevalence of carbapenem resis-
tance in this study, caution has to be exercised in its 
use in critically-ill hospitalized patients to check any 
Table 1. Antibiotic resistance pattern of Acinetobacter species isolated from different wards, 
expressed in percentage (%)
Antibiotic
Post-opera-
tive and others 
(n=154)
ICU
(n=89)
Burns (n=22)
Overall
(n=265)
ß-lactams
   Piperacillin 97.9 97.4 100.0 97.9
   Carbenicillin 69.6 71.4 50.0 68.8
   Cefotaxime 79.0 83.5 83.3 80.8
   Ceftazidime 77.6 83.5 83.3 80.0
   Cefoperazone 79.0 87.3 77.8 82.3
   Imipenem 07.1 12.3 09.1 09.1
   Meropenem 07.7 12.7 11.1 09.8
Aminoglycosides
   Gentamicin 83.9 87.3 94.4 85.8
   Tobramycin 82.5 86.0 88.9 84.2
   Amikacin 74.8 73.4 77.8 74.6
   Netilmicin 78.3 83.5 83.3 80.4
Quinolones
   Ciprofloxacin 79.7 83.5 77.8 80.8
   Norfloxacin 78.3 71.4 100.0 78.1
Others
   Cefoperazone +    
      sulbactam 27.8 45.6 27.8 31.2
ICU=Intensive care unitGaur A et al. Carbapenem-resistant Acinetobacter species
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Table 2. Clinical data of patients producing carbapenem-resistant Acinetobacters
Sl. no. Sample Ward/ICU Age (years) Sex Clinical diagnosis
1 Pus FSW 45 F Gall bladder perforation
2 Pus MSW 34 M Non-healing ulcer
3 Pus MSW 33 F Polytrauma
4 Pus Spl 50 M Diabetic foot
5 Blood NICU   1 M Neonatal septicaemia
6 Pus Tr 32 M Crush injury
7 Pus Ortho   7 F Abscess Rt knee
8 Pus MSW 33 M Non-healing ulcer
9 Pus Gyn 28 F PO infection
10 Swab ICU 26 M Multiple fracture
11 ETT ICU 50 F Renal failure
12 ETT ICU 61 M ARDS, with PUO
13 ETT ICU 21 F Respiratory failure
14 Urine NICU 12 days M UTI 
15 ETT ICU 35 M COPD
16 Pus MSW 55 M Necrotizing fascitis 
17 Pus ICU 45 M Road traffic accident
18 Pus FSW 35 M Abdominal surgery
19 Pus MSW 41 M Laparotomy
20 Pus Burns 70 M 90% burn
21 Pus NICU   1 month M Cellulitis
22 ETT ICU 10 F Head injury
23 ETT ICU 35 M Bronchial asthma
24 Tr. tube ICU 30 M Pneumonia
25 Pus CTVS 45 M Infective endocarditis
26 Pus Burns 30 F 70% burn
27 Urine Gyn 22 F PO infection
28 ETT ICU 32 M COPD, complications
29 Pus MSW 44 M Abdominal surgery
30 Tr. tube ICU 43 F Bronchial asthma
31 ETT ICU 70 M Pneumonia
32 Pus Spl 48 M Bracheal artey injury
33 Urine ICU 29 M Laparatomy
34 Pus Surg 27 F Deglobing injury scalp
35 Cat. tip ICU 48 F Opium poisoning
36 ETT ICU 35 F GI bleeding, pneumonia
37 Swab ICU 22 M Renal failure
38 ETT ICU 43 F Pneumonia
39 Blood ICU 47 M Septicaemia
ARDS=Acute respiratory distress syndrome; Cat=Catheter; COPD=Chronic obstructive pulmo-
nary disease; CTVS=Cardiovascular thoracic surgery; ETT=Endotracheal tube; FSW=Female surgi-
cal ward; GI=Gastrointestinal; Gyn=Gynaecology; ICU=Intensive care unit; MSW=Male surgical 
ward, NICU=Neonatal ICU, PO=Postoperative; Ortho=Orthopaedics; PUO=Pyrexia of unknown 
origin; Spl=Special ward; Tr=Tracheostomy; UTI=Urinary tract infection Gaur A et al. Carbapenem-resistant Acinetobacter species
Volume 26 | Number 2 | June 2008 187
further increase in the resistance to carbapenems. It 
is notable that almost 45% isolates of Acinetobacter 
species were on the borderline to moderate/resis-
tant range to carbapenem. Regular monitoring and 
documentation of carbapenem resistance is, there-
fore, crucial while developing strategies to control 
infections due to Acinetobacter spp. in hospitalized 
patients.
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